Tumor‐infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions

Cancer · Published 2026-07-21 · DOI 10.1002/cncr.70526

Free full text

Authors (6)

Shen Li, Alexandra E. Rojek, Reid Shaw, Cristina O’Donoghue, J. Michael Millis, Daniel J. Olson

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Li, S., Rojek, A., Shaw, R., et al. (2026). Tumor‐infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions. Cancer. https://doi.org/10.1002/cncr.70526

Related articles

• New data inform decision‐making for breast cancer surgeries · Cancer · 2026 · Same journal
• DELII: Ultralow‐dose nivolumab extended overall survival after prior systemic therapy · Cancer · 2026 · Same journal
• Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B‐cell lymphoma, including the post‐CAR T‐cell therapy setting: A meta‐analysis · Cancer · 2026 · Same journal
• Most older patients with advanced cancer prioritize QOL over extending survival · Cancer · 2026 · Same journal
• Demographic, birth, parental characteristics, and the risk of early‐onset colorectal cancer: A population‐based nested case‐control study in California · Cancer · 2026 · Same journal
• First‐line CDK4/6 inhibitors fail to improve overall survival in advanced breast cancer · Cancer · 2026 · Same journal
• HER2 ‐targeting zongertinib shows early activity in untreated advanced HER2 ‐mutant NSCLC · Cancer · 2026 · Same journal
• EXPRESSION OF CONCERN: Prolyl Hydroxylase‐2 (PHD2) Exerts Tumor‐Suppressive Activity in Pancreatic Cancer† · Cancer · 2026 · Same journal
• Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma · Cancer · 2026 · Same journal
• Sexual health behaviors and contraceptive practices among Canadian childhood, adolescent, and young adult cancer survivors and controls · Cancer · 2026 · Same journal